Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as salmeterol 50mcg, Salmeterol 50mcg, salmeterol and fluticasone propionate, Salmeterol Inhalation Powder
Salmeterol · 5 trials · 2 indications
| Name | Type | Description |
|---|---|---|
| montelukast (5mg QD) | DRUG | - |
| Salmeterol/Fluticasone propionate Inhalation Powder (50/100mcg BID) | DRUG | - |
| Salmeterol/fluticasone propionate 50/500mcg Diskus | DRUG | - |
| Salmeterol 50mcg/ Fluticasone Propionate 500mcg | DRUG | - |
| Salmeterol/Fluticasone propionate combination product | DRUG | - |
| Fluticasone propionate | DRUG | - |
| salmeterol | DRUG | - |
| tiotropium | DRUG | - |
| GSK233705 | DRUG | - |
Inclusion criteria: * Diagnosis of asthma for at least 6 months (per American Thoracic Society \[ATS\] definition). * Best forced expiratory volume in one second (FEV1) between 55% and 80% of predicted normal. * More than or 12% FEV1 reversibility following inhalation of salbutamol. * Must also be ...
Salmeterol is a small molecule being studied for the treatment of Chronic Obstructive Pulmonary Disease (COPD). It has been evaluated in clinical trials involving patients with this condition, with studies conducted across multiple countries. The drug is in clinical development for respiratory use.
Salmeterol is developed by GSK plc, a pharmaceutical company listed on the stock exchange under the ticker GSK. The company is conducting clinical research on this drug for the treatment of Chronic Obstructive Pulmonary Disease.
Salmeterol has completed Phase 3 clinical trials for Chronic Obstructive Pulmonary Disease. The drug is investigational and has been studied in clinical development programs. It has not been described as approved, and it remains in clinical research.
Salmeterol has been studied in three completed clinical trials. These include NCT00268177, which examined airway inflammation in COPD patients, and NCT00268216, which evaluated survival in subjects with COPD. A third trial, NCT00422604, assessed safety and efficacy of salmeterol in combination with another investigational drug.
Salmeterol is not the same as GSK233705. In one clinical trial, NCT00422604, salmeterol was studied in combination with GSK233705, which is a separate investigational compound. The trial compared this combination against other treatments in patients with COPD.